Structural Biology Shared Service

20.0摘要：结构生物学共享服务 结构生物学共享服务(SBSS)帮助研究人员收集和解释 结构生物学数据来自三项技术-低温电子显微镜、X射线结晶学、 和核磁共振--作为推进癌症生物学研究的增值手段。SBSS 支持马里兰大学马琳分校和斯图尔特·格林鲍姆分校所有五个研究项目的用户 综合癌症中心(UMGCCC)来自SBSS的结构生物学数据帮助研究人员推导出 癌症相关蛋白和酶的分子作用机制以及允许分子设计 药物，包括作为研究研究和潜在癌症治疗候选药物的分子探针。 这三种技术为理解结构和生物分子提供了互补的方法 行动机制。SBSS领导层的专业知识将调查人员引导到适当的结构 生物学方法(S)，将最有效地解决他们的科学问题，然后为 获得高质量的分析。SBSS的使用量很大。例如，18个研究小组使用两个或更多 结构分析方法。SBSS与其他公司合作促进UMGCCC早期药物发现 由MacKerell(MSB)领导的计算机辅助药物设计中心(CADDC)； 以及由韦伯(MSB)领导的生物分子治疗中心(CBT)。教务监督 由SBSS用户和外部审查员组成的委员会评估并提供关于当前 服务和战略规划。总体而言，SBSS为UMGCCC调查人员提供了访问最先进的 协作环境中的结构生物学仪器是基于基本结构的药物的理想选择 设计研究，以推动高影响力的癌症研究和从病床到床边的成功。在……里面 2019年SBSS支持了56名研究人员的研究，其中40人(71.4%)隶属于UMGCCC。2019年 SBSS为UMGCCC提供了1790万美元的资金，所有这些资金都经过了同行审查。2015-2019年，SBSS 支持164种出版物，包括在《科学》、《细胞》、《PNAS》、《核酸》等影响较大的期刊上发表的出版物 《美国化学学会杂志》和《分子生物学杂志》。

20.0 Abstract: Structural Biology Shared Service The Structural Biology Shared Service (SBSS) assists investigators in the collection and interpretation of structural biology data derived from three technologies—cryogenic electron microscopy, X-ray crystallography, and nuclear magnetic resonance—as a value-added means to advance cancer biology research. SBSS supports users from all five research programs at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). The structural biology data from SBSS help investigators derive the molecular mechanisms of action of cancer-related proteins and enzymes and permit the design of molecular agents, including molecular probes as drug candidates for research studies and potential cancer treatments. The three technologies offer complementary approaches to understanding structure and biomolecule mechanisms of action. The expertise of SBSS leadership directs investigators to the appropriate structural biology method(s) that will most efficiently address their scientific questions and then provides strategies for obtaining high-quality analysis. SBSS is heavily used. For example, 18 research groups use two or more structural analysis methods. SBSS facilitates early-stage UMGCCC drug discovery in cooperation with other UMGCCC shared services; the Computer Aided Drug Design Center (CADDC), headed by MacKerell (MSB); and the Center for Biomolecular Therapeutics (CBT), directed by Weber (MSB). The Faculty Oversight Committee, composed of SBSS users and external reviewers, assesses and provides guidance on current services and strategic planning. Overall, SBSS provides UMGCCC investigators with access to state-of-the-art structural biology instrumentation in a collaborative environment that is ideal for basic structure-based drug design research to enable the advancement of high-impact cancer research and bench-to-bedside success. In 2019 SBSS supported studies by 56 investigators, 40 (71.4%) of whom were affiliated with UMGCCC. In 2019 SBSS supported $17.9 million of UMGCCC funding, all of which was peer reviewed. From 2015 to 2019, SBSS supported 164 publications including those in high-impact journals such as Science, Cell, PNAS, Nucleic Acids Research, Journal of the American Chemical Society, and Journal of Molecular Biology.